Emergent BioSolutions (NYSE:EBS - Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.40, Zacks reports. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The firm had revenue of $194.70 million during the quarter, compared to analyst estimates of $254.67 million. During the same quarter in the prior year, the business posted ($0.77) EPS. Emergent BioSolutions updated its FY 2025 guidance to EPS.
Emergent BioSolutions Stock Performance
EBS traded up $0.04 during trading on Thursday, hitting $5.84. 1,268,798 shares of the company traded hands, compared to its average volume of 2,660,899. The firm has a market cap of $316.22 million, a P/E ratio of -1.42 and a beta of 1.62. The stock's fifty day moving average is $9.38 and its 200 day moving average is $9.00. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a one year low of $1.82 and a one year high of $15.10.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on EBS shares. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday. Benchmark upped their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, StockNews.com lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday.
Check Out Our Latest Stock Report on Emergent BioSolutions
Emergent BioSolutions Company Profile
(
Get Free Report)
Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
See Also
Before you consider Emergent BioSolutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent BioSolutions wasn't on the list.
While Emergent BioSolutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
